Luseogliflozin - Taisho Pharmaceutical
Alternative Names: Lusefi; Luseogliflozin hydrate; TS-071Latest Information Update: 06 Dec 2021
At a glance
- Originator Taisho Pharmaceutical
- Class Antihyperglycaemics; Glucosides; Phenyl ethers; Small molecules; Sugar alcohols; Sulfides
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 06 Dec 2021 Taisho Pharmaceutical completes a phase III trial in Type-2-diabetes-mellitus (In children, In adolescent) in Japan (PO, Tablet) (JapicCTI-184022)
- 30 Sep 2021 Luseogliflozin is still in phase III trial in Type-2-diabetes-mellitus (In children, In adolescent) in Japan before September 2021 (PO, Tablet) (JapicCTI-184022)
- 28 Aug 2021 No recent reports of development identified for clinical-Phase-Unknown development in Type-2-diabetes-mellitus(In children, In adolescent) in Japan (PO, Tablet)